OXiGENE, Inc.
OXGN, a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer, announced that enrollment has been completed in
a randomized Phase 2 clinical trial testing the combination of ZYBRESTAT®
(fosbretabulin; CA-4P) plus bevacizumab to treat patients with advanced
ovarian cancer. This trial, GOG-0186I, is being conducted by the Gynecologic
Oncology Group (GOG) under the sponsorship of Cancer Therapy Evaluation
Program (CTEP) of the National Cancer Institute (NCI). This is the first and
currently the only randomized trial to test an antiangiogenic therapeutic
agent combined with a vascular disrupting agent in ovarian cancer, without
including any cytotoxic chemotherapy. The fosbretabulin tromethamine is being
provided to CTEP under a Cooperative Research and Development Agreement
(CRADA) with OXiGENE and the bevacizumab is being provided under a CRADA with
Genentech, Inc.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in